Paganin, M <br/><br/>
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.  [electronic resource] 

 -  Leukemia  Dec 2008 
 - 2193-200 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/leu.2008.227  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Asparaginase--therapeutic use<br/>Child<br/>Child, Preschool<br/>Combined Modality Therapy<br/>Cyclophosphamide--therapeutic use<br/>Cytarabine--therapeutic use<br/>Daunorubicin--therapeutic use<br/>Disease-Free Survival<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Infant<br/>Male<br/>Mercaptopurine--therapeutic use<br/>Methotrexate--therapeutic use<br/>Multivariate Analysis<br/>Neoplasm, Residual--drug therapy<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Predictive Value of Tests<br/>Prednisone--therapeutic use<br/>Prognosis<br/>Prospective Studies<br/>Recurrence<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Risk Factors<br/>Survival Analysis<br/>Treatment Outcome<br/>Vincristine--therapeutic use